Drew Spaventa, the CEO of Singular Genomics discusses disruptive new technologies in the sequencing market and how new market entrants such as Singular Genomics are changing the competitive landscape with lower cost, higher throughput equipment. In this video Drew talks about the barriers to entry for new entrants given Illumina’s historic hold on the sequencing by synthesis market following the acquisition of Solexa in 2007. Key topics discussed include the competitive journey of the G4 sequencing platform, the sequencing ecosystem in terms of software, library prep chemistries, and sequencing reagents, flow cell design, the evolution of the customer landscape in sequencing, other new competitive entrants such as Ultima, Element, and Apton (acquired by Pacific Biosciences), potential acquirers of nascent life science tools companies such as Roche and Thermo Fisher, and the changing cost structure for whole exome and whole genome sequencing.